PI3K/Akt/mTOR Signaling
PI3K/Akt/mTOR signaling inhibitors are compounds that target the phosphoinositide 3-kinase (PI3K), Akt kinase, and mammalian target of rapamycin (mTOR) pathways. These pathways are critical regulators of cell growth, survival, metabolism, and autophagy, making them key targets in cancer research and metabolic disorders. Inhibiting these pathways can help to control tumor growth and proliferation, offering potential therapeutic strategies for various cancers and other diseases characterized by dysregulated cell signaling. At CymitQuimica, we offer a comprehensive selection of high-quality PI3K/Akt/mTOR inhibitors to support your research in oncology, cellular signaling, and metabolic diseases.
Subcategories of "PI3K/Akt/mTOR Signaling"
- AMPK(158 products)
- ATM/ATR(71 products)
- DNA-PK(51 products)
- EGFR(572 products)
- MELK(7 products)
- PDK(9 products)
- PI3K(242 products)
- S6 Kinase(9 products)
- gsk-3(112 products)
- mTOR(144 products)
Show 2 more subcategories
Found 1038 products of "PI3K/Akt/mTOR Signaling"
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
NVP-BBD130
CAS:<p>NVP-BBD130 is a stable, ATP-competitive, potent, orally active inhibitor of PI3K and mTOR.</p>Formula:C28H21N5OColor and Shape:SolidMolecular weight:443.5EGFR/HER2-IN-3
CAS:<p>EGFR/HER2-IN-3 (Compound ZINC21942954) is a dual EGFR and HER2 inhibitor.</p>Formula:C26H23N5O3Color and Shape:SolidMolecular weight:453.49DNA-PK-IN-7
CAS:<p>DNA-PK-IN-7 is a potent DNA-PK inhibitor (IC50= 1 nM) (WO2021104277A1, compound 5).</p>Formula:C19H21N9O2Color and Shape:SolidMolecular weight:407.43eCF-309
CAS:<p>eCF-309 is a potent mTOR inhibitor with IC50 value of 15 nM.</p>Formula:C18H21N7O3Color and Shape:SolidMolecular weight:383.4EGFR-IN-31
CAS:<p>EGFR-IN-31: Potent EGFR inhibitor, targets mutations & overexpression in NSCLC; potential cancer research compound. (WO2021185298A1, 2)</p>Formula:C32H36FN7O2Color and Shape:SolidMolecular weight:569.67PDZ1i
CAS:<p>PDZ1i: potent MDA-9/Syntenin inhibitor; crosses blood-brain barrier; targets GBM, FAK, EGFRvIII; lowers MMP secretion.</p>Formula:C28H26N8O4Color and Shape:SolidMolecular weight:538.56BIBX 1382 Dihydrochloride
CAS:<p>BIBX 1382 Dihydrochloride blocks Lassa/Ebola entry, aids in studying virus-host interactions, and hints at kinase targets for therapy.</p>Formula:C18H21Cl3FN7Color and Shape:SolidMolecular weight:460.76LDC0496
CAS:<p>LDC0496: Potent EGFR/Her2 exon 20 inhibitor; selective for wild-type EGFR, kinase-specific.</p>Formula:C32H35N5O3Color and Shape:SolidMolecular weight:537.65EGFR-IN-69
CAS:<p>EGFR-IN-69: Potent EGFR inhibitor for NSCLC research; IC50: 4.3-25.6 nM against various EGFR mutations.</p>Formula:C31H37Cl2N7O3SColor and Shape:SolidMolecular weight:658.64PfGSK3/PfPK6-IN-2
CAS:<p>PfGSK3/PfPK6-IN-2 inhibits Plasmodium falciparum GSK3/PK6 (IC50: 172 nM/11 nM) for Malaria research.</p>Formula:C24H25Cl2N5OSColor and Shape:SolidMolecular weight:502.46EGFR-IN-63
CAS:<p>EGFR- IN-63 is an EGFR inhibitor with an IC50 value of 0.096 μM. EGFR- IN-63 exhibited anticancer effects on MCF-7 cells (IC50: 2.49 μM).</p>Formula:C20H12BrN5SColor and Shape:SolidMolecular weight:434.31PI3Kδ-IN-3
CAS:<p>PI3Kδ-IN-3 (TC KHNS 11) is a PI3Kδ inhibitor with an IC50 value of 9 nM.PI3Kδ-IN-3 has a favorable pharmacokinetic profile and inhibits B cell function.</p>Formula:C28H24N6O3Purity:98.43%Color and Shape:SolidMolecular weight:492.53EMI48
CAS:<p>EMI48, a derivative of EMI1, exhibits increased efficacy against mutant EGFR compared to EMI1. It specifically inhibits EGFR triple mutants [1].</p>Formula:C21H20N2O3Color and Shape:SolidMolecular weight:348.4OXA-01
CAS:<p>OXA-01 is a potent mTORC1 and mTORC2 inhibitor, with IC 50 values of 29 nM and 7 nM, respectively [1]. OXA-01 demonstrates broad anti-tumor activity.</p>Formula:C21H20ClN5O2Color and Shape:SolidMolecular weight:409.87BRD1652
CAS:<p>BRD1652 is a highly selective and potent GSK3 inhibitor.</p>Formula:C20H20F3N3OPurity:98%Color and Shape:SolidMolecular weight:375.39CC260
CAS:<p>CC260 selectively inhibits PI5P4Kα/β (Ki: 40/30 nM), with minimal effect on Plk1/RSK2, useful for metabolic, diabetes, and cancer studies.</p>Formula:C24H29Cl2N5O2Color and Shape:SolidMolecular weight:490.43AS2541019
CAS:<p>AS2541019 is a selective Phosphatidylinositol-3-kinase p110δ (PI3Kδ) inhibitor.</p>Formula:C26H33F2N7O3Color and Shape:SolidMolecular weight:529.58CHMFL-PI4K-127
CAS:<p>CHMFL-PI4K-127 (15g) selectively inhibits PfPI4K (IC50=0.9 nM), potent against Plasmodium 3D7 (EC50=25.1 nM), with oral anti-malaria activity.</p>Formula:C18H15ClN4O3SColor and Shape:SolidMolecular weight:402.85EGFR-IN-54
CAS:<p>EGFR-IN-54 (Compound 3c) is a potent inhibitor of EGFR (IC50: 1.623 μM) and is toxic to cancer cells.</p>Formula:C17H14N4O4S3Color and Shape:SolidMolecular weight:434.51EGFR-IN-25
CAS:<p>EGFR-IN-25, an efficacious EGFR inhibitor, demonstrates IC50 values of 9 nM for BaF3 cells (EGFR DEL19/T790M/C797S) and 60 nM for A431 cells (WT), respectively.</p>Formula:C34H43N9O2Color and Shape:SolidMolecular weight:609.76EMI56
CAS:<p>EMI56, a derivative of EMI1, exhibits enhanced potency against mutant EGFR compared to EMI1. Additionally, EMI56 effectively inhibits EGFR triple mutants[1].</p>Formula:C21H20N2O3Color and Shape:SolidMolecular weight:348.4EGFR-IN-39
CAS:<p>EGFR-IN-39, an acrylamide, is a potent EGFR inhibitor and antitumor agent targeting NSCLC with low toxicity. See WO2021185348A1 for details.</p>Formula:C24H25ClN6O3Color and Shape:SolidMolecular weight:480.95JBJ-09-063 hydrochloride
<p>JBJ-09-063 hydrochloride: targeted EGFR inhibitor, effective for various mutations and TKI-resistant lung cancer models.</p>Formula:C31H30ClFN4O3SColor and Shape:SolidMolecular weight:593.11EGFR/HER2-IN-2
CAS:<p>EGFR/HER2-IN-2 (Compound ZINC35560729) is a dual EGFR and HER2 inhibitor that acts on both EGFR (IC50: 5.02 μM) and HER2 (IC50: 0.83 μM).</p>Formula:C26H23N5O3Color and Shape:SolidMolecular weight:453.49SIC-19
CAS:<p>SIC-19, a SIK2 inhibitor, functions by promoting the degradation of SIK2 protein via the ubiquitination pathway. It inhibits the growth of cancer cells and sensitizes cells, ovarian cancer organoids, and xenograft models to PARP inhibitors (such as Olaparib).</p>Formula:C29H26N4O5S2Color and Shape:SolidMolecular weight:574.67EGFR-IN-21
CAS:<p>EGFR-IN-21, a potent EGFR inhibitor, exhibits an IC50 of 0.38 nM, demonstrating significant antitumor activity.</p>Formula:C36H44BrN10O2PColor and Shape:SolidMolecular weight:759.68PI3Ka-IN-5
CAS:<p>PI3Ka-IN-5 is a potent PI3Kα/mTOR inhibitor, with an IC 50 of 0.7 nM and 3.3 nM, respectively. PI3Ka-IN-5 can be used for the research of colorectal cancer .</p>Formula:C30H35N9O5Color and Shape:SolidMolecular weight:601.66EGFR mutant-IN-2
CAS:<p>EGFR mutant-IN-2 (Compound D51) is an inhibitor of EGFR mutants, specifically targeting EGFR L858R/T790M/C797S and EGFR del19/T790M/C797S mutants with IC50 values of 14 nM and 62 nM, respectively. This compound exhibits favorable pharmacokinetic (PK) parameters, safety properties, in vivo stability, and demonstrates antitumor activity [1].</p>Formula:C27H27F3N6O2SColor and Shape:SolidMolecular weight:556.6ON 146040
CAS:<p>ON 146040 is an effective inhibitor of PI3K isoforms with IC50s of 14 and 20 nM for PI3Kα and PI3Kδ, respectively.</p>Formula:C24H23N7O3SPurity:97.39%Color and Shape:SolidMolecular weight:489.55P-2281
CAS:<p>P-2281 is an mTOR inhibitor with anticancer and anti-inflammatory properties.P-2281 inhibits dextran sulfate sodium (DSS)-induced colitis by suppressing T-cell</p>Formula:C9H8ClN3OPurity:99.95%Color and Shape:SolidMolecular weight:209.63PI3K/mTOR Inhibitor-13
CAS:<p>PI3K/mTOR Inhibitor-13, an oral dual blocker of PI3K and mTOR, may treat sexual diseases, solid tumors, and IPF.</p>Formula:C20H13F2N5O3SColor and Shape:SolidMolecular weight:441.41PI3Kα/mTOR-IN-1
CAS:<p>PI3Kα/mTOR-IN-1 is a potent dual inhibitor of PI3Kα/mTOR.</p>Formula:C16H18N6OPurity:99.89%Color and Shape:SolidMolecular weight:310.35EGFR-IN-2
CAS:<p>EGFR-IN-2 is a oral and mutation-selective EGFR inhibito,NSCLC, with high selectivity for resistant single and double mutant T790M.</p>Formula:C26H33N9O3SPurity:98.52% - 99.79%Color and Shape:SolidMolecular weight:551.66Mutated EGFR-IN-2
CAS:<p>Mutated EGFR-IN-2 is an inhibitor of mutant-selective EGFR.</p>Formula:C29H35FN8O3Purity:98%Color and Shape:SolidMolecular weight:562.64PI3K/mTOR Inhibitor-8
CAS:<p>PI3K/mTOR Inhibitor-8: Dual PI3Kα (IC50: 0.46 nM) & mTOR (IC50: 12 nM) inhibitor; blocks G1/S phase & induces apoptosis in HCT-116 cells.</p>Formula:C23H22N8O4SColor and Shape:SolidMolecular weight:506.54PI3K-IN-38
CAS:<p>PI3K-IN-38: oral PI3K inhibitor, IC50 of 0.541 µM, anticancer, anti-inflammatory, halts tumors in vivo.</p>Formula:C20H24N6O2Purity:99.89%Color and Shape:SolidMolecular weight:380.44AMPK activator 4
CAS:<p>Potent, selective AMPK activator 4 enhances glucose tolerance and insulin sensitivity without affecting mitochondrial complex I.</p>Formula:C24H21ClN2O3Purity:99.46% - 99.65%Color and Shape:SolidMolecular weight:420.89Tyrphostin AG 112
CAS:<p>Tyrphostin AG 112 is an inhibitor of EGFR phosphorylation.</p>Formula:C13H8N4OPurity:97.01%Color and Shape:SolidMolecular weight:236.23PI3K-IN-9
CAS:<p>PI3K-IN-9 is a potent and selective inhibitor of PI3Kδ(IC50 of 8.9 nM).</p>Formula:C19H23N7OPurity:98%Color and Shape:SolidMolecular weight:365.43EGFR-IN-53
CAS:<p>EGFR-IN-53 (Compound 7) is a potent inhibitor of EGFR (IC50 = 8.264 μM) that exhibits cytotoxic activity against cancer cell lines [1].</p>Formula:C14H13N3O2SColor and Shape:SolidMolecular weight:287.34PI3K-IN-10
CAS:<p>PI3K-IN-10 is a potent inhibitor of pan-PI3K .</p>Formula:C23H19ClN6OPurity:98%Color and Shape:SolidMolecular weight:430.89PI3Kγ inhibitor 1
CAS:<p>PI3Kγ inhibitor 1 is a inhibitor of PI3Kδ and PI3Kγ.</p>Formula:C32H26N8O2SPurity:98%Color and Shape:SolidMolecular weight:586.67EGFR/C797S-IN-1
CAS:<p>EGFR/C797S-IN-1: Potent EGFR-C797S inhibitor, IC50 of 0.128 µM, dose-dependent p-EGFR suppression, anti-tumor properties.</p>Formula:C28H30N4O3Color and Shape:SolidMolecular weight:470.56PI3-Kinase α Inhibitor 2
CAS:<p>Phosphatidylinositol 3-kinase (PI3K) catalyzes the phosphorylation of the 3' hydroxyl position of PIs to produce the second messengers PtdIns-(3,4)-P2 and</p>Formula:C16H15N3O2SColor and Shape:SolidMolecular weight:313.37EGFR-IN-5
CAS:<p>EGFR-IN-5 inhibits EGFR & mutants; IC50: EGFR 10.4nM, L858R 1.1nM, L858R/T790M 34nM, L858R/T790M/C797S 7.2nM.</p>Formula:C31H38FN9OPurity:98.17%Color and Shape:SolidMolecular weight:571.69PI3Kδ/γ-IN-1
CAS:<p>PI3Kδ/γ-IN-1 is a selective and effective inhibitor of PI3Kδ/γ that can be used in the treatment of hematologic malignancies.</p>Formula:C25H28N6O4SColor and Shape:SolidMolecular weight:508.59PP30
CAS:<p>PP30 is an inhibitor of mTORC1 and mTORC2. It is selective within the PI3K family, inhibiting other PI3Ks only at high concentrations.</p>Formula:C18H19N7OSPurity:98%Color and Shape:SolidMolecular weight:381.45PI3K/mTOR Inhibitor-3
CAS:<p>PI3K/mTOR Inhibitor-3, a potent dual-action anti-cancer imidazoline, targets PI3K and mTOR.</p>Formula:C22H23N5OColor and Shape:SolidMolecular weight:373.45DIF-3
CAS:<p>DIF-3 activates GSK-3β, degrades cyclin D1/c-Myc, and inhibits Wnt/β-catenin in DLD-1 cells, curbing HeLa cell proliferation.</p>Formula:C13H17ClO4Purity:99.57%Color and Shape:SolidMolecular weight:272.72EHT 1610
CAS:<p>EHT 1610 (EHT 5372) is a potent inhibitor of DYRK, with an IC50 of 0.36 nM and 0.59 nM for DYRK1A and DYRK1B, respectively.</p>Formula:C18H14FN5O2SPurity:98.59%Color and Shape:SolidMolecular weight:383.4
